FDA cleared the CorPath 200 System to be used in percutaneous coronary interventions. The system is designed to assist interventional cardiologists in performing PCI.
“We are pleased to have received clearance from the FDA for the world’s first system designed for robotic-assisted PCI procedures,” said David M. Handler, president and CEO of Corindus Vascular Robotics, in the release. “This is an important milestone for interventional cardiology as we take the next step in transforming the way these procedures are performed in the future. The CorPath System offers hospitals the opportunity to bring robotic-assisted technology benefits to their coronary patients and their physicians.”
Corindus Vascular Robotics is headquartered in Natick, Mass.
Related Articles on FDA Clearance:
Siemens Receives FDA Clearance for MRI System
Roche Receives FDA Clearance for Insulin Pump Therapy System
GE Healthcare Receives FDA Clearance for Cardiac Spectral CT
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
